This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

Sponsored by Revance Therapeutics, Inc.

About this trial

Last updated 11 years ago

Study ID

RT001-CL019

Status

Completed

Type

Interventional

Phase

Phase 3

Placebo

Yes

Accepting

18-75 Years
18 to 65 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 12 years ago

What is this trial about?

This study will evaluate the efficacy and safety of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines.

What are the participation requirements?

Yes

Inclusion Criteria

- Moderate to severe crow's feet lines

- Female or male, 18 to 65 years of age and in good general health

- Women of childbearing potential (WOCBP) must agree to use an effective method of birth control during the course of the study

No

Exclusion Criteria

- Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A

- Muscle weakness or paralysis, particularly in the area receiving study treatment

- Active skin disease or irritation at the treatment area

- Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated by manually spreading the skin apart

- Treatment with botulinum toxin type A for crow's feet lines in the last 6 months

Locations

Location

Status